John Taverner

John Taverner

Auto-generated profile, based on publicly available information

John Taverner

Lung Transplant Service, Alfred Hospital and Monash University, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2024 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
RSRob Stirling
Rob Stirling
AHAmelia Harrison
Amelia Harrison
JHJoanna Huang
Joanna Huang
VLVera Lee
Vera Lee
JTJohn Taverner
John Taverner
HBHayley Barnes
Hayley Barnes
Background: Lung cancer diagnosis, staging and treatment may be enhanced by multidisciplinary participation and presentation in multidisciplinary meetings (MDM). We performed a systematic review and meta-analysis to explore literature evidence of clinical impacts of MDM exposure.Methods: A study protocol was registered (PROSPERO identifier CRD42021258069). Randomised controlled trials and observational cohort studies including adults with nonsmall cell lung cancer and who underwent MDM review, compared to no MDM, were included. MEDLINE, CENTRAL, Embase andClinicalTrials.govwere searched on 31 May 2021. Studies were screened and extracted by two reviewers. Outcomes included time to diagnosis and treatment, histological confirmation, receipt of treatments, clinical trial participation, survival and quality of life. Risk of bias was assessed using the ROBINS-I (Risk of Bias in Non-randomised Studies – of Interventions) tool.Results: 2947 citations were identified, and 20 studies were included. MDM presentation significantly increased histological confirmation of diagnosis (OR 3.01, 95% CI 2.30–3.95; p<0.00001) and availability of clinical staging (OR 2.55, 95% CI 1.43–4.56; p=0.002). MDM presentation significantly increased likelihood of receipt of surgery (OR 2.01, 95% CI 1.29–3.12; p=0.002) and reduced the likelihood of receiving no active treatment (OR 0.32, 95% CI 0.21–0.50; p=0.01). MDM presentation was protective of both 1-year survival (OR 3.23, 95% CI 2.85–3.68; p<0.00001) and overall survival (hazard ratio 0.63, 95% CI 0.55–0.72; p<0.00001).Discussion: MDM presentation was associated with increased likelihood of histological confirmation of diagnosis, documentation of clinical staging and receipt of surgery. Overall and 1-year survival was better in those presented to an MDM, although there was some clinical heterogeneity in participants and interventions delivered. Further research is required to determine the optimal method of MDM presentation, and address barriers to presentation.

1 April 2016 in Journal of Bronchology & Interventional Pulmonology
Verified
Journal Article
Closed access
JTJohn Mbbs Taverner
John Mbbs Taverner
MCMun-Yoong Mbbs Cheang
Mun-Yoong Mbbs Cheang
PAPhillip Fracs Antippa
Phillip Fracs Antippa
KSKatharine Mbbs See
Katharine Mbbs See
LILouis B. Mbbs Irving
Louis B. Mbbs Irving
DSDaniel Paul Steinfort
Daniel Paul Steinfort
Background: Confirmation of mediastinal disease (N2/3) in non–small cell lung cancer (NSCLC) generally precludes curative surgical management. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has become a routine first test in mediastinal staging of NSCLC; however, it remains unclear whether a negative EBUS-TBNA should be followed by mediastinoscopy before proceeding to surgery. Understanding the prevalence of metastases in lymph nodes with benign findings on EBUS-TBNA will inform decision making following negative EBUS-TBNA. Methods: We examined a retrospective cohort of patients who underwent EBUS-TBNA before resection with mediastinal lymph node sampling for NSCLC between December 2009 and June 2014 in 3 hospitals in Melbourne, Australia. All patients had integrated positron emission tomography/computed tomography (PET/CT) before EBUS-TBNA. Results: Eighty-two matched mediastinal lymph node stations were sampled in 57 patients by both EBUS-TBNA and surgical resection, 47 nodes in patients staged cN0/1 by PET/CT and 35 nodes in patients staged cN2/3. All patients had a negative EBUS-TBNA. Four malignant nodes were identified surgically (4.9% of lymph nodes). The mean size of malignant deposits was 5.5 mm. Per-node negative predictive value was 78/82=0.95. All malignant nodes were located in patients with moderate-high risk disease (cN2/3), giving a disease prevalence in cN2/3 patients of 11%, and 0% in cN0/1. In patients staged cN2, per-node NVP was 0.89. Conclusion: The prevalence of mediastinal nodal disease following negative EBUS-TBNA is very low, at 4.9%. The per-node NVP of EBUS-TBNA is 0.95, decreasing to 0.89 in moderate-high risk patients. We suggest that a negative EBUS-TBNA of mediastinal nodes does not need to be confirmed by mediastinoscopy of those nodal stations, regardless of PET/CT findings.

24 January 2019 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
JTJohn Taverner
John Taverner
LRLauren Ross
Lauren Ross
CBClaire Bartlett
Claire Bartlett
MLMarco Luthe
Marco Luthe
JOJeffrey Ong
Jeffrey Ong
NSNatasha Smallwood
Natasha Smallwood

14 February 2024 in Respirology
Verified
Journal Article
Closed access
JTJohn Taverner
John Taverner
CLCarmen M. Lucena
Carmen M. Lucena
JGJustin L. Garner
Justin L. Garner
COChristopher M. Orton
Christopher M. Orton
ANAndrew G. Nicholson
Andrew G. Nicholson
PSPallav L. Shah
Pallav L. Shah

16 June 2020 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
LRLauren Ross
Lauren Ross
JTJohn Taverner
John Taverner
JJJennifer John
Jennifer John
ABAndreas Baisch
Andreas Baisch
LILouis Irving
Louis Irving
NSNatasha Smallwood
Natasha Smallwood

17 March 2026 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
GSGregory I. Snell
Gregory I. Snell
BLBronwyn J. Levvey
Bronwyn J. Levvey
NNNobenguni Ndiweni
Nobenguni Ndiweni
LSLucy Stewart
Lucy Stewart
LSLucy C. Sullivan
Lucy C. Sullivan
CTClaire Thomson
Claire Thomson